A gout genetic risk test examines inherited variants that influence serum urate and the likelihood of developing gout. Most tests focus on common variants in urate-transport genes such as SLC2A9 and ABCG2, often combining many variants into a polygenic risk score. These results can help explain why gout clusters in families or occurs despite only modest dietary triggers, but they do not diagnose gout, measure the amount of urate in the body, or prove that a painful joint is caused by urate crystals. Gout develops through a sequence: persistent hyperuricemia permits monosodium urate crystals to form, and the immune system then reacts to those crystals with sudden inflammation. Kidney function, medicines, alcohol, body weight, metabolic health, age, sex, ancestry, and diet can all modify that pathway. The most useful interpretation therefore combines genetics with symptoms, serum urate measurements, examination, imaging when needed, and sometimes joint-fluid crystal analysis.
- Gout susceptibility is usually polygenic rather than caused by one deterministic mutation.
- SLC2A9 and ABCG2 affect how the kidneys and intestines handle urate.
- A high genetic risk score does not confirm gout, and a low score does not rule it out.
- HLA-B*58:01 is a separate medication-safety test related to allopurinol hypersensitivity.
- Treatment decisions are guided mainly by clinical gout, serum urate, kidney health, and treatment response.
Table of Contents
- How Gout Develops
- SLC2A9, ABCG2, and Urate Transport
- What Gout Genetic Testing Measures
- Who May Consider Testing
- Understanding Genetic Risk Results
- Diagnosing Gout Beyond Genetics
- Treatment, Pharmacogenetics, and Monitoring
- Family Risk and Practical Prevention
How Gout Develops
Gout is an inflammatory arthritis caused by monosodium urate crystals. Urate is the end product of purine metabolism in humans. It circulates in blood and is removed mainly through the kidneys, with an important contribution from the intestine. When production and intake exceed elimination for long enough, serum urate rises. Above its saturation range, urate can crystallize in joints, bursae, tendons, and other tissues.
Hyperuricemia is necessary for typical gout, but it is not identical to gout. Many people have an elevated serum urate level without ever developing a flare. Others accumulate crystals silently for years before the first attack. Whether crystals form depends on the height and duration of urate elevation, local temperature, tissue conditions, prior joint injury, and other biological factors. Whether a deposit produces severe pain depends on innate immune activation around the crystals.
A gout flare commonly begins abruptly, often overnight, with intense pain, swelling, warmth, and redness. The first metatarsophalangeal joint at the base of the big toe is classic, but ankles, knees, wrists, fingers, elbows, and other sites may be affected. Untreated attacks can recur. Over time, persistent crystal burden can cause chronic inflammatory arthritis, joint damage, and visible or palpable deposits called tophi. Urate stones may also form in the urinary tract.
Genetics contributes at several points in this process. The largest inherited effects usually involve transporters that control renal or intestinal urate handling. Additional variants affect purine metabolism, kidney function, inflammation, and the biological response to crystals. These inherited effects interact with common exposures and medical conditions, including chronic kidney disease, obesity, insulin resistance, hypertension, diuretic use, high alcohol intake, fructose-sweetened beverages, and purine-rich foods.
It is therefore inaccurate to describe gout as simply a dietary disease. Diet can alter risk and trigger flares, but a person with strongly reduced urate excretion may develop gout despite a generally balanced diet. Conversely, a person with favorable urate handling may tolerate more exposure without reaching the same serum urate level. Genetics helps explain variation between people; it does not make lifestyle irrelevant or inevitable.
SLC2A9, ABCG2, and Urate Transport
SLC2A9 encodes glucose transporter 9, commonly called GLUT9. Despite its name, this transporter has a major role in urate movement. It is expressed in the kidney and other tissues and participates in renal urate reabsorption. Common variants near or within SLC2A9 are among the strongest inherited influences on serum urate identified in genome-wide studies. Their average effect is meaningful at a population level but remains probabilistic for an individual.
A risk-increasing SLC2A9 allele may shift a person’s usual urate upward, especially when combined with other variants or environmental pressures. Rare damaging variants in SLC2A9 can produce unusual low-urate disorders with excessive renal urate loss, which is biologically different from the common-variant risk assessed by most consumer gout reports. A result should therefore specify the exact variant and whether the test is evaluating common susceptibility alleles or a rare monogenic condition.
ABCG2 encodes an ATP-binding cassette transporter that exports urate and many other molecules. It contributes to urate excretion through both the intestine and kidney. The well-studied p.Gln141Lys variant, often represented by the marker rs2231142, reduces transporter function. Carriers can have higher serum urate, earlier gout, and a greater chance of disease when other risk factors are present. ABCG2 dysfunction is particularly relevant to extra-renal urate underexcretion because intestinal elimination becomes less efficient.
ABCG2 has also been investigated as a contributor to response variability with urate-lowering medicines. Such associations are not yet a substitute for measuring serum urate and titrating treatment. A person should not stop, avoid, or select a gout medicine solely from an ABCG2 susceptibility result unless a clinician is using a validated pharmacogenetic recommendation for that exact drug and variant.
Other genes often included in gout panels or polygenic scores include SLC22A12, which encodes the renal urate transporter URAT1; SLC17A1 and related renal transport genes; SLC22A11; PDZK1; and loci involved in kidney and metabolic biology. Each common allele usually has a modest effect. The combined pattern matters more than any one marker, except in rare disorders in which a highly penetrant pathogenic variant disrupts a specific urate pathway.
The same genetic variant can have different apparent effects across studies because allele frequencies, environmental exposures, sex distribution, age, and background genetic architecture vary. For that reason, a laboratory should state the ancestry groups used to build and validate its risk model. A score developed largely in one ancestry may classify risk less accurately in another and can create false reassurance or unnecessary alarm.
What Gout Genetic Testing Measures
There is no single standard “gout gene test.” The phrase may refer to several different products, and they answer different questions.
A targeted common-variant test checks selected markers, often in SLC2A9 and ABCG2. It may report whether each allele is associated with higher or lower average urate. This format is easy to understand but captures only a fraction of inherited susceptibility. It should not be interpreted as a complete genetic assessment.
A polygenic risk score combines dozens, hundreds, or many thousands of variants, weighting them according to associations observed in a reference study. The result may be expressed as a percentile, standard-deviation score, relative risk, or category such as average, increased, or decreased genetic predisposition. These labels depend on the laboratory’s reference population and model. A score at the 90th percentile means the modeled inherited burden is higher than that of most people in the reference group; it does not mean there is a 90% chance of gout.
Some broad sequencing panels analyze rare variants in urate transport or purine-metabolism genes. These tests may be appropriate when a clinician suspects an unusual inherited syndrome, such as very early hyperuricemia, recurrent uric acid stones, unexpectedly low urate, kidney injury related to urate handling, or a strong family pattern that does not resemble ordinary multifactorial gout. Sequencing is not routinely required for typical adult-onset gout.
The test itself usually uses saliva, a cheek swab, or blood. The laboratory extracts DNA, assays selected variants or performs sequencing, and applies its interpretation model. Genetics is stable over a lifetime, so the inherited result generally does not need repetition. The clinical meaning may change, however, as the person ages, develops kidney disease, starts a diuretic, gains or loses weight, changes alcohol intake, or receives new diagnoses.
A useful report should identify the variants tested, genome build and nomenclature, assay limitations, validation population, calculated metric, and whether the result has been reviewed for medical use. It should distinguish a research association from a clinically validated recommendation. Reports that provide only a colored risk category without methods are difficult to evaluate responsibly.
Who May Consider Testing
Most people with classic gout do not need a genetic susceptibility test to establish the diagnosis or choose initial treatment. The diagnosis can usually be evaluated with history, examination, serum urate, and crystal analysis or imaging when uncertainty remains. Standard care does not require SLC2A9 or ABCG2 genotyping before starting urate-lowering therapy.
Testing may still be considered for a person who wants to understand a strong family pattern, especially when gout began unusually early or occurs across several generations. A carefully explained polygenic score may show that inherited urate handling contributes to risk, but it rarely identifies a single cause. It may be more useful for education and motivation than for changing a prescription.
A specialist may order more focused genetic evaluation when gout or abnormal urate appears in childhood, adolescence, or early adulthood; when the phenotype is severe and disproportionate to usual risk factors; when there is recurrent nephrolithiasis or unexplained kidney disease; or when laboratory findings suggest a rare purine or transport disorder. In these situations, the question is not simply “How high is polygenic risk?” but “Could a specific inherited disorder explain this presentation?”
Family members of someone with gout generally do not require predictive DNA testing. A more direct approach is to review family history, medications, kidney health, blood pressure, metabolic risk, and serum urate when clinically appropriate. Genetic testing may be reasonable in a research setting or when a known rare pathogenic variant has already been identified in the family.
Medication-safety testing deserves separate consideration. Testing for HLA-B*58:01 may be recommended before allopurinol in populations with a higher prevalence of the allele and higher risk of allopurinol-associated severe cutaneous adverse reactions. U.S. rheumatology guidance conditionally recommends pre-treatment testing for people of Southeast Asian descent, including Han Chinese, Korean, and Thai ancestry, and for African American patients. Local guidance and ancestry terminology may differ, so decisions should reflect the patient’s background and regional recommendations.
HLA-B*58:01 testing is not a gout risk score. A positive result does not explain why urate is high, and a negative result does not guarantee that allopurinol cannot cause any adverse effect. It addresses a specific, rare, potentially life-threatening immune reaction. Kidney impairment, starting dose, concomitant medicines, and clinical monitoring remain important.
Genetic counseling can be helpful when testing involves rare disease, unexpected findings, uncertain variants, family testing, or questions about ancestry and score validity. Counseling should cover what the result can change, what it cannot answer, privacy considerations, and the possibility that a result will be inconclusive.
Understanding Genetic Risk Results
A higher-than-average polygenic score indicates that the tested combination of alleles is associated with higher serum urate or gout incidence in the model’s reference data. It may support an inherited contribution when the personal or family history is suggestive. It does not show that crystals are present, predict the date of a first flare, or determine how severe disease will become.
The absolute meaning depends on baseline risk. Age, sex, ancestry, kidney function, body composition, alcohol exposure, medicines, and prior serum urate can change the chance that the genetic predisposition becomes clinically apparent. Two people with the same score may have very different outcomes. The most useful question is how the score modifies an already established clinical picture, not whether it replaces that picture.
An average score means the assayed variants resemble the central range of the reference population. It does not mean no inherited risk is present. The model may omit relevant variants, rare variants, structural changes, or family-specific biology. Average polygenic risk is also compatible with gout caused by kidney disease, diuretics, metabolic factors, or sustained dietary and alcohol exposure.
A lower-than-average score may suggest more favorable inherited urate handling, but it cannot exclude gout. A person can overcome that relative protection through sufficiently impaired kidney excretion, medicines, high cell turnover, or other factors. A low result should never be used to dismiss a hot swollen joint or avoid diagnostic assessment.
A report may list individual markers. One SLC2A9 or ABCG2 risk allele should be interpreted as a small component of a larger system. Terms such as “mutation” can be misleading for common polymorphisms that occur in healthy populations. The laboratory should report effect direction and confidence without implying that a common allele is a pathogenic Mendelian variant.
A pathogenic or likely pathogenic rare variant has a different meaning from a polygenic score. Its interpretation depends on the gene, inheritance pattern, mechanism, biochemical phenotype, and evidence linking it to a defined disorder. Confirmation and specialist review are appropriate before testing relatives or changing management.
A variant of uncertain significance, or VUS, is not a positive diagnosis. It should not be used by itself to label a person with an inherited urate disorder, prescribe treatment, or screen healthy relatives as though disease were established. Reclassification may occur as population data, functional studies, and family evidence accumulate.
For HLA-B*58:01, a positive result indicates substantially increased risk of allopurinol-induced severe cutaneous adverse reactions, and established pharmacogenetic guidance recommends avoiding allopurinol when reasonable alternatives are available. A negative result lowers allele-related risk but does not eliminate all hypersensitivity or routine medication risks. This pharmacogenetic interpretation must remain separate from the gout-susceptibility section of the report.
Diagnosing Gout Beyond Genetics
A gout genetic test cannot determine whether an acute joint attack is gout rather than septic arthritis, calcium pyrophosphate deposition disease, trauma, cellulitis, or another inflammatory condition. A newly hot, swollen joint—especially with fever, systemic illness, immune suppression, recent surgery, or a prosthetic joint—may require urgent evaluation because infection can damage a joint rapidly and can coexist with crystals.
The most definitive diagnostic evidence is identification of needle-shaped, negatively birefringent monosodium urate crystals in synovial fluid or material aspirated from a tophus. Joint aspiration also permits cell count, Gram stain, and culture when infection is a concern. Crystal analysis is especially valuable when the presentation is atypical or the consequences of diagnostic error are high.
Serum urate supports assessment but must be timed and interpreted correctly. A high level increases suspicion and helps quantify the treatment target. A normal result during an acute flare does not exclude gout because serum urate can fall temporarily during inflammation. If the value is below the expected range during a strongly suggestive flare, it is often repeated after the attack has settled.
Ultrasound can reveal a double-contour sign, tophi, and aggregates. Dual-energy computed tomography can identify urate deposits in selected cases. Imaging is useful when aspiration is not feasible or the diagnosis remains uncertain, but findings depend on disease duration and technical expertise. Plain radiographs may be normal early and show characteristic erosions only after longstanding disease.
Once gout is established, evaluation should include flare frequency, tophi, joint damage, kidney function, urinary stones, cardiovascular and metabolic comorbidities, current medicines, alcohol exposure, and barriers to adherence. Serum urate is followed over time because it reflects the modifiable biochemical driver. DNA does not change with successful treatment, whereas serum urate should.
Asymptomatic hyperuricemia requires a different discussion. In many people, elevated urate without gout or stones does not automatically lead to urate-lowering medication. Clinical guidelines differ in specific circumstances, and comorbid kidney or cardiovascular disease may prompt individualized review. A high polygenic score alone is not generally considered proof that preventive drug treatment is warranted.
Treatment, Pharmacogenetics, and Monitoring
Treatment has two distinct goals: control the inflammation of a flare and lower the long-term urate pool when urate-lowering therapy is indicated. Genetics may add context, but symptoms, comorbidities, contraindications, serum urate, and prior response determine most choices.
Acute flares are commonly treated with a nonsteroidal anti-inflammatory drug, colchicine, or a glucocorticoid. The safest option depends on kidney function, gastrointestinal bleeding risk, cardiovascular disease, anticoagulants, drug interactions, diabetes, and time since symptom onset. Rest, ice, and temporary protection of the affected joint may provide additional relief. Antibiotics do not treat crystal inflammation, but suspected infection must be assessed urgently.
Long-term urate-lowering therapy is strongly considered for people with tophi, radiographic damage attributable to gout, or frequent flares. It may also be discussed after a first flare in selected high-risk situations, such as marked hyperuricemia, kidney disease, or urolithiasis. The decision should be shared and should address the chronic nature of crystal deposition.
Allopurinol is a preferred first-line urate-lowering medicine in major guidelines, including for many people with chronic kidney disease. It is generally started at a low dose—lower still when kidney function is impaired—and increased gradually according to serum urate and tolerability. Starting low reduces adverse-event risk and helps patients adjust. Many people require a dose higher than an arbitrary “renal dose” ceiling to reach target, provided titration and monitoring are appropriate.
A treat-to-target strategy uses serial serum urate measurements to guide dose adjustment. A common target is below 6 mg/dL, equivalent to 360 micromol/L. A lower target, often below 5 mg/dL or 300 micromol/L, may be considered for severe gout, substantial tophi, or persistent flares. After stable control, monitoring intervals can lengthen, but ongoing adherence is needed because stopping therapy often permits urate to rise again.
Flares can temporarily become more frequent when urate-lowering therapy begins because deposits are being mobilized. Prophylaxis with low-dose colchicine, an NSAID, or another suitable anti-inflammatory strategy is often used during initiation and titration. Patients should be told that an early flare does not mean urate lowering has failed. Established therapy is usually continued through a flare unless a clinician identifies a specific reason to stop.
Febuxostat is another xanthine oxidase inhibitor. Uricosuric approaches increase renal urate excretion and may be appropriate in selected patients, but kidney function, stones, interactions, and local availability matter. People with difficult-to-control or severe tophaceous gout may need rheumatology care and advanced therapy.
HLA-B58:01 testing can influence allopurinol selection, but SLC2A9 or ABCG2 susceptibility results usually do not determine the drug or dose. A positive HLA-B58:01 result generally leads clinicians to choose an alternative when possible. Regardless of genotype, anyone starting allopurinol should seek prompt medical advice for rash, facial swelling, mucosal lesions, fever, or systemic illness and should not self-rechallenge after a suspected severe reaction.
Lifestyle measures support medication but should not be framed as blame. Gradual weight reduction when appropriate, moderation of beer and spirits, limiting sugar-sweetened beverages, avoiding dehydration, and reducing frequent large portions of high-purine animal foods may lower urate or flare risk. Dairy foods and a balanced dietary pattern can fit well. Medication review may identify a diuretic or other contributor, but necessary cardiovascular treatment should not be changed without the prescribing clinician.
Family Risk and Practical Prevention
Gout often clusters in families because relatives share many urate-related alleles as well as diet, medicines, body-weight patterns, and health conditions. A family history is clinically useful even when no DNA test is performed. First-degree relatives can be encouraged to know the symptoms of gout, maintain routine primary care, and discuss serum urate testing when they have risk factors or suggestive symptoms.
Routine genetic screening of healthy relatives is not standard for ordinary polygenic gout. A polygenic score does not provide a clear threshold at which medication should begin, and its accuracy may be uneven across ancestries. Checking blood pressure, kidney function, metabolic health, medication exposures, and serum urate often produces more actionable information.
When a rare pathogenic variant causing a defined urate disorder is found, targeted testing of relatives can be useful. The inheritance pattern determines who is at risk, and biochemical testing may accompany DNA analysis. This situation should be distinguished from finding one common ABCG2 or SLC2A9 allele in a consumer report.
Practical prevention starts with recognizing persistent hyperuricemia and modifiable contributors before crystal burden becomes advanced. People with prior flares should keep an agreed flare plan, know how to use prescribed medicine promptly, and attend follow-up for urate titration. Missing follow-up after the pain resolves is a common reason gout remains undertreated.
Genetic information can reduce stigma by showing that urate handling is partly inherited. It should not create fatalism. Even a person at high inherited risk can often prevent recurrent flares and dissolve existing crystal deposits by sustaining serum urate below target. Conversely, a favorable genetic result does not protect against every clinical exposure. The appropriate response to any result is proportionate monitoring, evidence-based diagnosis, and individualized treatment rather than fear or false reassurance.
References
- The genetics of gout: translation into clinical practice — 2025 review.
- Large-scale cross-ancestry genome-wide meta-analysis of serum urate — 2024 genome-wide association study.
- Gout and its management — 2024 clinical review.
- Gout: diagnosis and management — 2022 clinical guideline.
- 2020 American College of Rheumatology Guideline for the Management of Gout — 2020 clinical guideline.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update — 2016 pharmacogenetics guideline.
Disclaimer
This article is for general education and does not diagnose gout, interpret an individual laboratory report, or replace care from a qualified clinician. Genetic risk results should be considered with symptoms, serum urate, kidney function, medicines, ancestry, and validated clinical testing. A hot swollen joint with fever or systemic illness may require urgent assessment to exclude infection.
